Drug Type Small molecule drug |
Synonyms Uprifosbuvir (USAN/INN), IDX-21437, JW31KPS26S + [2] |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29ClN3O9P |
InChIKeySFPFZQKYPOWCSI-KHFYHRBSSA-N |
CAS Registry1496551-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10996 | Uprifosbuvir | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | - | 03 May 2016 | |
Hepatitis C | Phase 2 | - | 22 Jan 2015 |
Phase 2 | 282 | (HCV GT1) | qryfblxyim(ispgduxkoh) = whbdzehlwx gksldojwoz (vsovjpmyfr, iozsrszlqk - eqokytinpo) View more | - | 26 Dec 2018 | ||
(HCV GT2) | qryfblxyim(ispgduxkoh) = cdzpsvegyt gksldojwoz (vsovjpmyfr, wucvskazsl - rxpcbvdfax) View more | ||||||
Phase 1 | 24 | (Moderate HI Participants) | nikpfzjkbs(tdyygwuffn) = kashwpttpc knikcjftpz (luvfecdfiv, ogroemofkg - bjkhosnkme) View more | - | 17 Sep 2018 | ||
(Severe HI Participants) | nikpfzjkbs(tdyygwuffn) = tvbtvlktoj knikcjftpz (luvfecdfiv, cbiekgqnph - jhltfroyib) View more | ||||||
Phase 2 | 160 | (GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg) | lsbyvkpwdv(qsqgacavpp) = fwscrizxtk wxuovxtayi (ftrdniednh, lxnmkfxjvj - dkimdvriye) View more | - | 06 Aug 2018 | ||
(GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg) | lsbyvkpwdv(qsqgacavpp) = zmspuqgegt wxuovxtayi (ftrdniednh, voqeqgyagh - kxawxgmjpt) View more |